Embed Size (px)
DESCRIPTION
Program Goals. Gastric and Esophageal Cancer in the United States, 2013. REGARD Ramucirumab Monotherapy in Second-line Gastric/GEJ Cancer, Phase 3 Trial. REGARD Efficacy Results. RAINBOW Ramucirumab in Second-line Gastric/GEJ Cancer, Phase 3 Trial. - PowerPoint PPT Presentation
Citation preview
Program Goals
Gastric and Esophageal Cancer in the United States, 2013
REGARDRamucirumab Monotherapy in Second-line
Gastric/GEJ Cancer, Phase 3 Trial
REGARDEfficacy Results
RAINBOWRamucirumab in Second-line Gastric/GEJ
Cancer, Phase 3 Trial
